期刊
NEUROLOGY
卷 76, 期 3, 页码 280-286出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318207b1b9
关键词
-
资金
- Pfizer Inc
- Baxter International Inc.
- NIH (NIA)
- Eisai Inc.
- Lundbeck Inc.
- Ipsen
- Pierre Fabre Laboratories
- Nestle
- Novartis
- INSERM
- Alzheimer's Association
- Academy of Healthcare Education
- Alpha Plus
- AstraZeneca
- Cadmus Medea Inc.
- Glia Scientific Communication
- Janssen
- Medical Decision Point, LLC
- InforMed Direct Plc
- MedPlan Communications Inc.
- Elan Corporation
- Eli Lilly and Company
- Canadian Institutes of Health Research
- Pacific Alzheimer Research Foundation
- NIH
- Medivation, Inc.
- Sonexa Therapeutics, Inc.
- Zapaq Inc./CoMentis
- Inc./Athenagen
- Inc./Astellas Pharma Inc.
- Debiopharm Group
- GlaxoSmithKline
- AC Immune SA
- Avanir Pharmaceuticals
- Bristol-Myers Squibb
- Dainippon Sumitomo Pharma
- ExonHit Therapeutics
- Fujisawa Pharmaceutical Company
- Ltd./Astellas Pharma Inc.
- Genentech, Inc.
- Merck Serono
- Noven Pharmaceuticals, Inc.
- Ocera Therapeutics
- Prana Biotechnology Limited
- Schering-Plough Corp.
- Sepracor Inc.
- Suven Life Sciences Ltd.
- Transition Therapeutics Inc.
- Varinel
- State of Texas
- Elan Corporation/Wyeth
- NIH (NCRR)
- Medivation Inc.
- UCB
- Fondation pour la Recherche dans la Maladie d'Alzheimer
- Roche
- Servier
- Avid Radiopharmaceuticals, Inc.
- Danone
- Alzheimer French Fondation
- PHRC
- ANR
- Toulouse Gerontopole
- La Fondation IFRAD
- Allergan, Inc.
- Lundbeck, Inc.
- Dr. Willmar Schwabe GmbH Co.
- Wyeth
Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia. Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD. Results: General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods. Conclusion: A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population. Neurology (R) 2011; 76:280-286
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据